Featured Products

  1. Powering Production Of Viral Vector-Based Therapies 11/14/2025

    Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.

  2. CD34+ HSC LNP Kits 4/24/2025

    Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications.

  3. GenVoy-ILM™ T-Cell Kits For mRNA 4/24/2025

    Off-the-shelf, research use only lipid nanoparticle (LNP) reagents to deliver RNA into T-cells.

  4. A Comprehensive Upstream Platform For Gene Therapy Applications 5/6/2024

    Explore a variety of cell lines, high-performance cell culture media, and single-use bioreactors to suit your process needs for any cell type.

  5. AAV Manufacturing Workflow 10/20/2023

    Explore scalable and flexible single-use solutions from design to delivery that can help you overcome challenges throughout adeno-associated virus (AAV) manufacturing workflow.

  6. Single-Use System For Clinical And Commercial Production Of LNPs 7/21/2023

    Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.

  7. Automated, Single-Use System For Clinical And Commercial LNP Production 7/21/2023

    The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.

  8. Services For Advancing mRNA-LNPs From Bench To Clinic 2/27/2023

    Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications. Explore end-to-end biopharma services and systems.

  9. Complete Solutions For Every Step Of Pharmaceutical Development 1/12/2023

    By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.

  10. A Disruptive Technology Accelerating Drug Development 7/1/2022

    Ignite simplifies the transition into clinical programs by incorporating these fundamental process steps for scale up in the earliest stages of pre-clinical development.